do not combine dpp-4 inhibitors with glp-1 receptor agonists recommendation Frontiers | for treating T2DM DPP-4 and GLP-1 Combination: Safety

2021;23 Suppl 3:5-29

GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions

Significantly decreased insulin and insulin receptor expression was observed in postmortem AD brain tissue, and changes in downstream insulin signaling molecules, including decreased levels of IRS-1/2, PI3K, p-Akt (51, 54)

Dorothy A

These reports can be helpful, but theyre not the same as large studies designed to answer safety questions

I tried it, and Im not going to do that